Futura has developed a highly efficient and proprietary delivery technology DermaSys® for the absorption of active molecules through the skin. The DermaSys® technology was originally developed by Futura for use in our topical treatment for erectile dysfunction, MED2002. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
Futura has signed agreements with global pharmaceutical and healthcare groups for two pipeline products which incorporate the DermaSys® technology platform:
In September 2007, we signed an agreement with SSL International plc for the development and commercialisation of MED2002, our topically applied product for erectile dysfunction.
In June 2010, we signed an agreement with GlaxoSmithKline plc for the development and potential commercialisation of TPR100, our topically applied product for pain relief.
To further maximise the value of this asset, Futura has been evaluating its use with a range of compounds and in a range of indications.
In the process of developing PET500 and RAD100, Futura also expanded its DermaSys® delivery technology platform and produced a new and unique delivery system which does not contain water, DermaSys® AquaFree.